4-[hydroxy(pyridin-3-yl)methyl]benzonitrile | 1163683-60-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[hydroxy(pyridin-3-yl)methyl]benzonitrile
• 英文别名: (R,S)-4-(hydroxy(pyridin-3-yl)methyl)benzonitrile；4-[hydroxyl(pyridine-3-yl)methyl]-benzonitrile
• CAS: 1163683-60-0
• 化学式: C₁₃H₁₀N₂O
• 分子量: 210.235
• InChiKey: QQNQNPRUJXZUBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  56.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[hydroxy(pyridin-3-yl)methyl]benzonitrile 在 氯化亚砜 、 N,N-二异丙基乙胺 、 potassium iodide 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 4-[[4-(Cyclopropanecarbonyl)piperazin-1-yl]-pyridin-3-ylmethyl]benzonitrile
  参考文献：
  名称：

  Design, structure–activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi

  摘要：

  A scaffold hopping exercise undertaken to expand the structural diversity of the fenarimol series of anti-Trypanosoma cruzi (T. cruzi) compounds led to preparation of simple 1-[phenyl(pyridin-3-yl)methyl]piperazinyl. analogues of fenarimol which were investigated for their ability to inhibit T. cruzi in vitro in a whole organism assay. A range of compounds bearing amide, sulfonamide, carbamate/carbonate and aryl moieties exhibited low nM activities and two analogues were further studied for in vivo efficacy in a mouse model of T. cruzi infection. One compound, the citrate salt of 37, was efficacious in a mouse model of acute T. cruzi infection after once daily oral dosing at 20, 50 and 100 mg/kg for 5 days. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.050
• 作为产物：
  描述：

  3-吡啶甲醛 在 异丙基氯化镁 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-[hydroxy(pyridin-3-yl)methyl]benzonitrile
  参考文献：
  名称：

  WO2007/89679

  摘要：

  公开号：

文献信息

• [EN] INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR<br/>[FR] INHIBITEURS DE PRÉSENTATION D'ANTIGÈNE PAR HLA-DR
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021198283A1

  公开（公告）日：2021-10-07

  Chromanone compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the inhibition of antigen presentation by HLA-DR.

  Chromanone化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与HLA-DR抗原呈递抑制相关的疾病状态、疾病和症状的方法。
• Potassium Channel Inhibitors
  申请人：Hoffman Jacob M.

  公开号：US20090030043A1

  公开（公告）日：2009-01-29

  The present invention relates to tetraaryl methyl amine compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

  本发明涉及四芳基甲基胺化合物及其衍生物，具有结构式（I），可用作钾通道抑制剂治疗心律失常等疾病。
• Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease
  作者：Martine Keenan、Jason H. Chaplin、Paul W. Alexander、Michael J. Abbott、Wayne M. Best、Andrea Khong、Adriana Botero、Catherine Perez、Scott Cornwall、R. Andrew Thompson、Karen L. White、David M. Shackleford、Maria Koltun、Francis C. K. Chiu、Julia Morizzi、Eileen Ryan、Michael Campbell、Thomas W. von Geldern、Ivan Scandale、Eric Chatelain、Susan A. Charman

  DOI：10.1021/jm401610c

  日期：2013.12.27

  Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is an increasing threat to global health. Available medicines were introduced over 40 years ago, have undesirable side effects, and give equivocal results of cure in the chronic stage of the disease. We report the development of two compounds, 6 and (S)-7, with PCR-confirmed curative activity in a mouse model of established T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7. Compounds 6 and (S)-7 have potent in vitro activity, are noncytotoxic, show no adverse effects in vivo following repeat dosing, are prepared by a short synthetic route, and have druglike properties suitable for preclinical development.
• [EN] POTASSIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE
  申请人：MERCK & CO INC

  公开号：WO2007089679A2

  公开（公告）日：2007-08-09

  [EN] The present invention relates to tetraaryl methyl amine compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
  [FR] La présente invention concerne des composés tétra-arylméthylamine et leurs dérivés ayant la structure (I) utilisés comme inhibiteurs du canal potassique pour traiter des arythmies cardiaques, et similaires.